The objective of this study was to evaluate the role of (68)Ga-labeled [1, 4, 7, 10-tetraazacyclo... more The objective of this study was to evaluate the role of (68)Ga-labeled [1, 4, 7, 10-tetraazacyclododecane-1, 4, 7, 10-tetraacetic acid]-1-NaI(3)-octreotide (DOTA-NOC) PET/CT in the diagnosis and management of gastroenteropancreatic neuroendocrine tumors (NETs). One hundred nine patients (median age, 50 years) with gastroenteropancreatic NETs underwent (68)Ga-DOTA-NOC PET/CT. PET/CT was performed after injection of 132-222 MBq (4-6 mCi) of (68)Ga-DOTA-NOC. Images were evaluated by two experienced nuclear medicine physicians both qualitatively as well as quantitatively (maximum standardized uptake value [SUV(max)]). Results of PET/CT were compared with the results of conventional imaging. Histopathology results, when available, and follow-up PET/CT or conventional imaging with biochemical markers were considered to be the reference standards. Gallium-68-DOTA-NOC PET/CT showed sensitivity and specificity of 78.3% and 92.5%, respectively, for primary tumor and 97.4% and 100% for metastases. It was better than a conventional imaging modality for the detection of both primary tumor (p < 0.001) and metastases (p…
Society of Nuclear Medicine Annual Meeting Abstracts, May 1, 2010
ABSTRACT Objectives: Administration of radioactivity to children and young adults has been a matt... more ABSTRACT Objectives: Administration of radioactivity to children and young adults has been a matter of debate making it imperative to use the minimum dose wherever possible. However there is lack of consensus amongst thyroidologists about the ideal dosage of radioiodine for treating pediatric Graves disease We aimed to evaluate the success rate of a fixed dose of 185MBq of radioiodine in patients of Graves disease aged less than 20 years. Methods: 57 patients of Graves disease less than 20 years age who were treated with a fixed dose of 185 MBq (5mCi) radioiodine were followed up 3 monthly upto 12months. Success of first dose of 131I was defined as a biochemical as well as clinical euthyroid or hypothyroid status at 12 months post therapy follow up without the need for additional antithyroid drugs/surgery/further radioiodine. Clinical and/or biochemical hyperthyroidism at 12 months was considered as 1st dose failure.Gland size, duration of disease, treatment with antithyroid drugs and its duration, and RAIU were other factors considered during analysis. Results: 42 patients were 1st dose successes at 12month follow up while there were 15 1st dose failures. Thus the 1st dose success rate of a fixed dose of 185MBq radioiodine was 73.68%. Conclusions: Our data suggests that a fixed dose of 185 MBq in patients of pediatric Graves disease may be suboptimal and a higher dose/repeated small fixed doses of radioiodine may be necessary
Is there a need for the contrast-enhanced PET/computed tomography (CT) scan or is the low-dose, n... more Is there a need for the contrast-enhanced PET/computed tomography (CT) scan or is the low-dose, non-contrast-enhanced PET/CT scan sufficient? The topic has been debated time and again. Although low-dose noncontrast CT serves the purpose of simple anatomic correlation and attenuation correction of PET images, many times patients have to undergo additional contrast-enhanced diagnostic imaging modalities, which may lead to a delay in decision-making. In this review, the authors have addressed various such issues related to the use of contrast agents and special techniques of clinical interest based on their utility in dual-modality PET/CT.
Objectives: To evaluate response to therapy in patients with recurrent breast cancer with metasta... more Objectives: To evaluate response to therapy in patients with recurrent breast cancer with metastasis using F18-FDG PET-CT. Methods: In this study 52 patients of recurrent/metastatic breast cancer were retrospectively analyzed. The age range was 26 to 74 years (mean age 52.27 years). All patients had baseline PET-CT scan with recurrent/metastatic disease. All patients underwent chemotherapy with/without radiotherapy and/or surgery. Follow-up PET-CT scan was done 4-6 weeks after last cycle of chemotherapy, radiotherapy, surgery. Pre-treatment PET-CT was compared with post treatment PET-CT to evaluate treatment response. Decrease in SUV of more than 50% was considered as significant response, decrease in SUV of more than 25% was considered as partial response. Increase in SUV of more than 25% or appearance of new lesion(s) was considered as progression. Results: Of 52 patients, 38 showed significant response, 4 showed stable disease and remaining 10 patients showed progression of disea...
The management of the patients with carcinoma of an unknown primary represents a difficult challe... more The management of the patients with carcinoma of an unknown primary represents a difficult challenge in oncology. Metastatic cancers of unknown primary origin are characterised by a poor prognosis. Conventional radiological imaging allows only detection of 20%-27% of primary cancers. To evaluate the role of 18F-FDG PET/CT in detection of primary tumors in carcinoma of unknown primary site. Methods: In the present study, a total of 31 patients (22 males, 9 females; mean age 53.1 years) with biopsy or cytopathology proven metastatic carcinoma and negative conventional diagnostic procedures (CT, MRI or Panendoscopy) were included. All patients underwent whole body 18F-FDG PET/CT study. Patient data was retrospectively analysed. Histopathological diagnosis is kept as the gold standard. Hypermetabolic areas at the site of CT changes were considered as positive and rate of detection of primary site is evaluated. Among 31 patients, 18F-FDG PET/CT detected primary site in 14 patients. 18F-F...
Objectives: To evaluate the diagnostic accuracy of 18F-Fluorodeoxyglucose (18F-FDG) positron emis... more Objectives: To evaluate the diagnostic accuracy of 18F-Fluorodeoxyglucose (18F-FDG) positron emission tomography-computed tomography (PET-CT) for detecting recurrence in patients with skeletal Ewing sarcoma. Methods: We retrospectively analyzed data of 53 patients (Age: 20.1±10.5 years; 73.5%-males) who underwent 71 18F-FDG PET-CT studies for suspected recurrence (n=52) or for routine follow up (n=19) after primary therapy of skeletal Ewing sarcoma. 18F-FDG PET-CT studies were evaluated qualitatively and quantitatively [Maximum standardized uptake value (SUVmax)] by two nuclear medicine physicians in consensus. Sensitivity, specificity, predictive values and accuracy was calculated on per study basis. Clinical/ imaging follow up (minimum 6 months) and/or histopathology (when available) was taken as reference standard. Results: Of the total 71, 42 (59.1%) 18F-FDG PET-CT studies were positive for recurrence and 29 (40.9%) were negative for recurrence. Local recurrence was most common ...
Objectives: The aim of the present study was to compare the diagnostic efficacy of F18-FDG PET-CT... more Objectives: The aim of the present study was to compare the diagnostic efficacy of F18-FDG PET-CT with conventional imaging (CI) for the detection of recurrence in previously treated patients of endometrial carcinoma. Methods: A total of 20 endometrial carcinoma patients previously treated by surgery (20)/ radiotherapy (7)/or chemotherapy (4) and having suspected recurrence were analysed retrospectively. The mean age was 56.4±10 years (range: 38-77). Four patients were premenopausal and 16 were postmenopausal. All patients underwent F18-FDG PET-CT for recurrence suspected clinically and/or on CI. F18-FDG PET-CT studies were evaluated by two nuclear medicine physicians. Results of F18-FDG PET-CT were compared with CI (ultrasound/ CT/ MRI). Final diagnosis of recurrence was made by biopsy and/or clinical/imaging follow up. Results: Of 20 patients, 15 were found to have recurrence based on biopsy and/or clinical/imaging follow up. F18-FDG PET-CT was positive in 86.6% (13/15) of these p...
Objectives: The objective of this study was to evaluate the diagnostic performance of 68Ga-DOTANO... more Objectives: The objective of this study was to evaluate the diagnostic performance of 68Ga-DOTANOC PET/CT in patients with a clinically suspected or established diagnosis of Gastrinoma in whom the results of conventional imaging with computed tomography (CT) were either unrevealing or equivocal. Methods: 24 patients (14male, 10 female, mean age-45.9 yrs) were included in this retrospective analysis. Inclusion criteria were a clinical symptomatology suggestive of Gastrinoma, elevated serum Gastrin levels (median value-1261.5, range 239-9516) and negative (12 patients) or equivocal CT results (12 patients). Results: 68Ga-DOTANOC PET/CT turned positive in 17/24 patients. A detection rate of 41.7% was observed in patients who had no findings on CT (5/12). Of the remaining twelve patients who had doubtful lesions on CT imaging, 68Ga-DOTANOC PET/CT was considered abnormal in all patients, yielding a detection rate of 100%. Reference standard was established using a combination of histopat...
The aim of this study was to assess the value of (18F) FDG PET/CT in evaluation of patients with ... more The aim of this study was to assess the value of (18F) FDG PET/CT in evaluation of patients with Fever Of Unknown Origin (FUO). We retrospectively analysed clinical data and (18F) FDG PET scan of 48 patients over a period of 1 year. These patients met the revised definition criteria of FUO (febrile illness of greater than 3 weeks duration, temperature greater than 38.3 C and no diagnosis after appropriate in-patient or out-patient evaluation). Most of the patients recruited in this study had normal clinical and radiological examination. (18F) FDG PET was helpful in making a diagnosis in 24 patients. An infective/inflammatory cause of FUO was found in thirteen (27%) patients, a neoplasm in six (12.5%) patients, autoimmune cause in five (10.4%) patients. A definitive diagnosis could not be made in twenty four (50%) patients. Out of these 24 patients, 15 had normal PET/CT study, 9 had positive PET/CT findings but they lost in follow up and 2 died within 1month of PET/CT study without a...
Objectives: The aim of this study was to compare 68Ga-DOTANOC and 18F-DOPA in the evaluation of m... more Objectives: The aim of this study was to compare 68Ga-DOTANOC and 18F-DOPA in the evaluation of medullary thyroid carcinoma (MTC). Methods: Seventeen patients with MTC were prospectively enrolled and scheduled for 68Ga-DOTANOC and 18F-DOPA PET/CT within a time interval of three weeks between the two tests. Fourteen of these patients were post operative and were being evaluated for restaging or response evaluation. Rest of the three patients were being evaluated as inoperable neck mass (n=2) and retrosternal mass (n=1). No cytoreductive therapy (chemotherapy, radiotherapy) or surgical intervention was done in the time interval between the two studies. Serum calcitonin levels were obtained for each patient. The scans were reported independently by two nuclear medicine physicians blinded to clinical and biochemical information. Results: Overall, 68Ga-DOTANOC identified 16/16 positive patients with a sensitivity of 100%. 18F-DOPA was positive in 14 of these patients with a sensitivity o...
Objectives: The aim of this study was to assess the value of [18F] FDG PET/CT in evaluation of pa... more Objectives: The aim of this study was to assess the value of [18F] FDG PET/CT in evaluation of patients with fever of unknown origin (FUO). Methods: Retrospective analysis, over a period of 1 year, of the clinical data and [18F] FDG PET/CT scans of 50 patients OF FUO, 35 males (7-82yr) and 15 females (12-55yr), was done. All the Patients had inconclusive initial investigation. Any [18F] FDG accumulation, which could not be explained by physiological distribution,was considered as abnormal. Results: Abnormal foci of [18F] FDG uptake were found in 30 patients. Out of these,22 patients were confirmed later by other investigations or clinical follow up. An infective cause was found in 13 patients(26%),neoplasm in 4 patients(8%),noninfectious inflammatory cause in 5 patients(10%).A definitive diagnosis could not be made in 2 patients within a period of six month, in 1 patient fever subsided without any intervention, 3 patients lost in follow up and 2 died within 1month of PET/CT study wi...
The objective of this study was to evaluate the role of (68)Ga-labeled [1, 4, 7, 10-tetraazacyclo... more The objective of this study was to evaluate the role of (68)Ga-labeled [1, 4, 7, 10-tetraazacyclododecane-1, 4, 7, 10-tetraacetic acid]-1-NaI(3)-octreotide (DOTA-NOC) PET/CT in the diagnosis and management of gastroenteropancreatic neuroendocrine tumors (NETs). One hundred nine patients (median age, 50 years) with gastroenteropancreatic NETs underwent (68)Ga-DOTA-NOC PET/CT. PET/CT was performed after injection of 132-222 MBq (4-6 mCi) of (68)Ga-DOTA-NOC. Images were evaluated by two experienced nuclear medicine physicians both qualitatively as well as quantitatively (maximum standardized uptake value [SUV(max)]). Results of PET/CT were compared with the results of conventional imaging. Histopathology results, when available, and follow-up PET/CT or conventional imaging with biochemical markers were considered to be the reference standards. Gallium-68-DOTA-NOC PET/CT showed sensitivity and specificity of 78.3% and 92.5%, respectively, for primary tumor and 97.4% and 100% for metastases. It was better than a conventional imaging modality for the detection of both primary tumor (p < 0.001) and metastases (p…
The objective of this study was to evaluate the role of (68)Ga-labeled [1, 4, 7, 10-tetraazacyclo... more The objective of this study was to evaluate the role of (68)Ga-labeled [1, 4, 7, 10-tetraazacyclododecane-1, 4, 7, 10-tetraacetic acid]-1-NaI(3)-octreotide (DOTA-NOC) PET/CT in the diagnosis and management of gastroenteropancreatic neuroendocrine tumors (NETs). One hundred nine patients (median age, 50 years) with gastroenteropancreatic NETs underwent (68)Ga-DOTA-NOC PET/CT. PET/CT was performed after injection of 132-222 MBq (4-6 mCi) of (68)Ga-DOTA-NOC. Images were evaluated by two experienced nuclear medicine physicians both qualitatively as well as quantitatively (maximum standardized uptake value [SUV(max)]). Results of PET/CT were compared with the results of conventional imaging. Histopathology results, when available, and follow-up PET/CT or conventional imaging with biochemical markers were considered to be the reference standards. Gallium-68-DOTA-NOC PET/CT showed sensitivity and specificity of 78.3% and 92.5%, respectively, for primary tumor and 97.4% and 100% for metastases. It was better than a conventional imaging modality for the detection of both primary tumor (p < 0.001) and metastases (p…
Society of Nuclear Medicine Annual Meeting Abstracts, May 1, 2010
ABSTRACT Objectives: Administration of radioactivity to children and young adults has been a matt... more ABSTRACT Objectives: Administration of radioactivity to children and young adults has been a matter of debate making it imperative to use the minimum dose wherever possible. However there is lack of consensus amongst thyroidologists about the ideal dosage of radioiodine for treating pediatric Graves disease We aimed to evaluate the success rate of a fixed dose of 185MBq of radioiodine in patients of Graves disease aged less than 20 years. Methods: 57 patients of Graves disease less than 20 years age who were treated with a fixed dose of 185 MBq (5mCi) radioiodine were followed up 3 monthly upto 12months. Success of first dose of 131I was defined as a biochemical as well as clinical euthyroid or hypothyroid status at 12 months post therapy follow up without the need for additional antithyroid drugs/surgery/further radioiodine. Clinical and/or biochemical hyperthyroidism at 12 months was considered as 1st dose failure.Gland size, duration of disease, treatment with antithyroid drugs and its duration, and RAIU were other factors considered during analysis. Results: 42 patients were 1st dose successes at 12month follow up while there were 15 1st dose failures. Thus the 1st dose success rate of a fixed dose of 185MBq radioiodine was 73.68%. Conclusions: Our data suggests that a fixed dose of 185 MBq in patients of pediatric Graves disease may be suboptimal and a higher dose/repeated small fixed doses of radioiodine may be necessary
Is there a need for the contrast-enhanced PET/computed tomography (CT) scan or is the low-dose, n... more Is there a need for the contrast-enhanced PET/computed tomography (CT) scan or is the low-dose, non-contrast-enhanced PET/CT scan sufficient? The topic has been debated time and again. Although low-dose noncontrast CT serves the purpose of simple anatomic correlation and attenuation correction of PET images, many times patients have to undergo additional contrast-enhanced diagnostic imaging modalities, which may lead to a delay in decision-making. In this review, the authors have addressed various such issues related to the use of contrast agents and special techniques of clinical interest based on their utility in dual-modality PET/CT.
Objectives: To evaluate response to therapy in patients with recurrent breast cancer with metasta... more Objectives: To evaluate response to therapy in patients with recurrent breast cancer with metastasis using F18-FDG PET-CT. Methods: In this study 52 patients of recurrent/metastatic breast cancer were retrospectively analyzed. The age range was 26 to 74 years (mean age 52.27 years). All patients had baseline PET-CT scan with recurrent/metastatic disease. All patients underwent chemotherapy with/without radiotherapy and/or surgery. Follow-up PET-CT scan was done 4-6 weeks after last cycle of chemotherapy, radiotherapy, surgery. Pre-treatment PET-CT was compared with post treatment PET-CT to evaluate treatment response. Decrease in SUV of more than 50% was considered as significant response, decrease in SUV of more than 25% was considered as partial response. Increase in SUV of more than 25% or appearance of new lesion(s) was considered as progression. Results: Of 52 patients, 38 showed significant response, 4 showed stable disease and remaining 10 patients showed progression of disea...
The management of the patients with carcinoma of an unknown primary represents a difficult challe... more The management of the patients with carcinoma of an unknown primary represents a difficult challenge in oncology. Metastatic cancers of unknown primary origin are characterised by a poor prognosis. Conventional radiological imaging allows only detection of 20%-27% of primary cancers. To evaluate the role of 18F-FDG PET/CT in detection of primary tumors in carcinoma of unknown primary site. Methods: In the present study, a total of 31 patients (22 males, 9 females; mean age 53.1 years) with biopsy or cytopathology proven metastatic carcinoma and negative conventional diagnostic procedures (CT, MRI or Panendoscopy) were included. All patients underwent whole body 18F-FDG PET/CT study. Patient data was retrospectively analysed. Histopathological diagnosis is kept as the gold standard. Hypermetabolic areas at the site of CT changes were considered as positive and rate of detection of primary site is evaluated. Among 31 patients, 18F-FDG PET/CT detected primary site in 14 patients. 18F-F...
Objectives: To evaluate the diagnostic accuracy of 18F-Fluorodeoxyglucose (18F-FDG) positron emis... more Objectives: To evaluate the diagnostic accuracy of 18F-Fluorodeoxyglucose (18F-FDG) positron emission tomography-computed tomography (PET-CT) for detecting recurrence in patients with skeletal Ewing sarcoma. Methods: We retrospectively analyzed data of 53 patients (Age: 20.1±10.5 years; 73.5%-males) who underwent 71 18F-FDG PET-CT studies for suspected recurrence (n=52) or for routine follow up (n=19) after primary therapy of skeletal Ewing sarcoma. 18F-FDG PET-CT studies were evaluated qualitatively and quantitatively [Maximum standardized uptake value (SUVmax)] by two nuclear medicine physicians in consensus. Sensitivity, specificity, predictive values and accuracy was calculated on per study basis. Clinical/ imaging follow up (minimum 6 months) and/or histopathology (when available) was taken as reference standard. Results: Of the total 71, 42 (59.1%) 18F-FDG PET-CT studies were positive for recurrence and 29 (40.9%) were negative for recurrence. Local recurrence was most common ...
Objectives: The aim of the present study was to compare the diagnostic efficacy of F18-FDG PET-CT... more Objectives: The aim of the present study was to compare the diagnostic efficacy of F18-FDG PET-CT with conventional imaging (CI) for the detection of recurrence in previously treated patients of endometrial carcinoma. Methods: A total of 20 endometrial carcinoma patients previously treated by surgery (20)/ radiotherapy (7)/or chemotherapy (4) and having suspected recurrence were analysed retrospectively. The mean age was 56.4±10 years (range: 38-77). Four patients were premenopausal and 16 were postmenopausal. All patients underwent F18-FDG PET-CT for recurrence suspected clinically and/or on CI. F18-FDG PET-CT studies were evaluated by two nuclear medicine physicians. Results of F18-FDG PET-CT were compared with CI (ultrasound/ CT/ MRI). Final diagnosis of recurrence was made by biopsy and/or clinical/imaging follow up. Results: Of 20 patients, 15 were found to have recurrence based on biopsy and/or clinical/imaging follow up. F18-FDG PET-CT was positive in 86.6% (13/15) of these p...
Objectives: The objective of this study was to evaluate the diagnostic performance of 68Ga-DOTANO... more Objectives: The objective of this study was to evaluate the diagnostic performance of 68Ga-DOTANOC PET/CT in patients with a clinically suspected or established diagnosis of Gastrinoma in whom the results of conventional imaging with computed tomography (CT) were either unrevealing or equivocal. Methods: 24 patients (14male, 10 female, mean age-45.9 yrs) were included in this retrospective analysis. Inclusion criteria were a clinical symptomatology suggestive of Gastrinoma, elevated serum Gastrin levels (median value-1261.5, range 239-9516) and negative (12 patients) or equivocal CT results (12 patients). Results: 68Ga-DOTANOC PET/CT turned positive in 17/24 patients. A detection rate of 41.7% was observed in patients who had no findings on CT (5/12). Of the remaining twelve patients who had doubtful lesions on CT imaging, 68Ga-DOTANOC PET/CT was considered abnormal in all patients, yielding a detection rate of 100%. Reference standard was established using a combination of histopat...
The aim of this study was to assess the value of (18F) FDG PET/CT in evaluation of patients with ... more The aim of this study was to assess the value of (18F) FDG PET/CT in evaluation of patients with Fever Of Unknown Origin (FUO). We retrospectively analysed clinical data and (18F) FDG PET scan of 48 patients over a period of 1 year. These patients met the revised definition criteria of FUO (febrile illness of greater than 3 weeks duration, temperature greater than 38.3 C and no diagnosis after appropriate in-patient or out-patient evaluation). Most of the patients recruited in this study had normal clinical and radiological examination. (18F) FDG PET was helpful in making a diagnosis in 24 patients. An infective/inflammatory cause of FUO was found in thirteen (27%) patients, a neoplasm in six (12.5%) patients, autoimmune cause in five (10.4%) patients. A definitive diagnosis could not be made in twenty four (50%) patients. Out of these 24 patients, 15 had normal PET/CT study, 9 had positive PET/CT findings but they lost in follow up and 2 died within 1month of PET/CT study without a...
Objectives: The aim of this study was to compare 68Ga-DOTANOC and 18F-DOPA in the evaluation of m... more Objectives: The aim of this study was to compare 68Ga-DOTANOC and 18F-DOPA in the evaluation of medullary thyroid carcinoma (MTC). Methods: Seventeen patients with MTC were prospectively enrolled and scheduled for 68Ga-DOTANOC and 18F-DOPA PET/CT within a time interval of three weeks between the two tests. Fourteen of these patients were post operative and were being evaluated for restaging or response evaluation. Rest of the three patients were being evaluated as inoperable neck mass (n=2) and retrosternal mass (n=1). No cytoreductive therapy (chemotherapy, radiotherapy) or surgical intervention was done in the time interval between the two studies. Serum calcitonin levels were obtained for each patient. The scans were reported independently by two nuclear medicine physicians blinded to clinical and biochemical information. Results: Overall, 68Ga-DOTANOC identified 16/16 positive patients with a sensitivity of 100%. 18F-DOPA was positive in 14 of these patients with a sensitivity o...
Objectives: The aim of this study was to assess the value of [18F] FDG PET/CT in evaluation of pa... more Objectives: The aim of this study was to assess the value of [18F] FDG PET/CT in evaluation of patients with fever of unknown origin (FUO). Methods: Retrospective analysis, over a period of 1 year, of the clinical data and [18F] FDG PET/CT scans of 50 patients OF FUO, 35 males (7-82yr) and 15 females (12-55yr), was done. All the Patients had inconclusive initial investigation. Any [18F] FDG accumulation, which could not be explained by physiological distribution,was considered as abnormal. Results: Abnormal foci of [18F] FDG uptake were found in 30 patients. Out of these,22 patients were confirmed later by other investigations or clinical follow up. An infective cause was found in 13 patients(26%),neoplasm in 4 patients(8%),noninfectious inflammatory cause in 5 patients(10%).A definitive diagnosis could not be made in 2 patients within a period of six month, in 1 patient fever subsided without any intervention, 3 patients lost in follow up and 2 died within 1month of PET/CT study wi...
The objective of this study was to evaluate the role of (68)Ga-labeled [1, 4, 7, 10-tetraazacyclo... more The objective of this study was to evaluate the role of (68)Ga-labeled [1, 4, 7, 10-tetraazacyclododecane-1, 4, 7, 10-tetraacetic acid]-1-NaI(3)-octreotide (DOTA-NOC) PET/CT in the diagnosis and management of gastroenteropancreatic neuroendocrine tumors (NETs). One hundred nine patients (median age, 50 years) with gastroenteropancreatic NETs underwent (68)Ga-DOTA-NOC PET/CT. PET/CT was performed after injection of 132-222 MBq (4-6 mCi) of (68)Ga-DOTA-NOC. Images were evaluated by two experienced nuclear medicine physicians both qualitatively as well as quantitatively (maximum standardized uptake value [SUV(max)]). Results of PET/CT were compared with the results of conventional imaging. Histopathology results, when available, and follow-up PET/CT or conventional imaging with biochemical markers were considered to be the reference standards. Gallium-68-DOTA-NOC PET/CT showed sensitivity and specificity of 78.3% and 92.5%, respectively, for primary tumor and 97.4% and 100% for metastases. It was better than a conventional imaging modality for the detection of both primary tumor (p < 0.001) and metastases (p…
Uploads
Papers by Aftab Nazar